Entity

Time filter

Source Type


Caldas H.C.,Laboratory of Immunology and Experimental Transplantation LITEX | Hayashi A.P.C.,Laboratory of Immunology and Experimental Transplantation LITEX | Abbud-Filho M.,Laboratory of Immunology and Experimental Transplantation LITEX | Abbud-Filho M.,Laboratory of Immunology and Transplantation Experimental LITEX
Transplantation Proceedings | Year: 2011

The increasing number of patients who suffer from chronic kidney diseases combined with the organ shortage have directed the attention of researchers to new alternatives in the fields of regenerative medicine including cell-based therapies and tissue bioengineering. This review of renal regenerative medicine addresses the mechanisms of action by stem cells to regenerate or repair chronically damaged renal tissue, alternative routes for their delivery, the role of biomaterials in tissue engineering, and the potential therapeutic effects of combining cell therapy with biomaterials. Despite the promise of ongoing work for therapy of chronic renal failure, caution is required as a large gap still exists between scientific knowledge and clinical translation for safe, effective stem cell-based therapies. © 2011 Published by Elsevier Inc. Source


Caldas H.C.,Laboratory of Immunology and Transplantation Experimental LITEX | Fernandes I.M.M.,Laboratory of Immunology and Transplantation Experimental LITEX | Kawasaki-Oyama R.S.,Laboratory of Immunology and Transplantation Experimental LITEX | Baptista M.A.S.F.,Laboratory of Immunology and Transplantation Experimental LITEX | And 6 more authors.
Experimental Biology and Medicine | Year: 2011

Different routes for the administration of bone marrow-derived cells (BMDC) have been proposed to treat the progression of chronic renal failure (CRF). We investigated whether (1) the use of bovine pericardium (BP) as a scaffold for cell therapy would retard the progression of CRF and (2) the efficacy of cell therapy differently impacts distinct degrees of CRF. We used 2/3 and 5/6 models of renal mass reduction to simulate different stages of chronicity. Treatments consisted of BP seeded with either mesenchymal or mononuclear cells implanted in the parenchyma of remnant kidney. Renal function and proteinuria were measured at days 45 and 90 after cell implantation. BMDC treatment reduced glomerulosclerosis, interstitial fibrosis and lymphocytic infiltration. Immuno-histochemistry showed decreased macrophage accumulation, proliferative activity and the expression of fibronectin and a-smooth muscle-actin. Our results demonstrate: (1) biomaterial combined with BMDC did retard the progression of experimental CRF; (2) cellular therapy stabilized serum creatinine (sCr), improved creatinine clearance and 1/sCr slope when administered during the less severe stages of CRF; (3) treatment with combined therapy decreased glomerulosclerosis, fibrosis and the expression of fibrogenic molecules; and (4) biomaterials seeded with BMDC can be an alternative route of cellular therapy. © 2011 by the Society for Experimental Biology and Medicine. Source

Discover hidden collaborations